期刊文献+

1H-咪唑并[4,5-c]喹啉衍生物的合成

Synthesis of Derivatives of 1H-Imidazoquinoline
下载PDF
导出
摘要 以1-(2-甲基丙基)-4-氯-1H-咪唑并[4,5-c]喹啉(Ⅰ)为原料与哌啶反应合成了1-(2-甲基丙基)-4-[哌啶-1-基]-1H-咪唑并[4,5-c]喹啉(Ⅱ),当用甲苯为溶剂,n(Ⅰ)∶n(哌啶)∶n(K2CO3)=1∶2∶0.3时,Ⅱ的收率为88.5%;Ⅰ与三倍过量的吗啉反应合成1-(2-甲基丙基)-4-[吗啉-4-基]-1H-咪唑并[4,5-c]喹啉(Ⅲ),收率86.5%;Ⅰ与三倍过量的哌嗪在体积分数50%的1,4-二氧六环水溶液中反应合成1-(2-甲基丙基)-4-[哌嗪-1-基]-1H-咪唑并[4,5-c]喹啉(Ⅳ),收率59%。Ⅱ、Ⅲ、Ⅳ的合成工艺均较简单。 1-( 2-Methylpropyl ) -4-( piperidin-l-yl ) -1H- imidazo [ 4, 5-c ] quinoline ( 11 ) was synthesized by the reaction of 1 -(2-methylpropyl) -4-chloro -1H- imidazo [ 4,5-c ] quinoline ( I ) with piperidine,when toluene was used as solvent and the molar ratio of Ⅰ ,piperidine and K2CO3 was 1:2: 0.3. The yield was 88.5%. 1-( 2-Methylpropyl ) -4-( morpholin-4-yl ) -1H-imidazo [ 4,5-c ] quinoline ( Ⅲ) was synthesized in 86.5% yield by the reaction of I with three fold excess of morpholine. 1-(2- Methylpropyl) -4-(piperazin-l-yl) -1 H- imidazo [ 4,5-c ] quinoline ( Ⅳ ) was obtained in 59% yield by the reaction of Ⅰwith three fold excess of piperazine using 50% water solution of 1,4-dioxane as solvent.
出处 《精细化工》 EI CAS CSCD 北大核心 2007年第3期304-307,共4页 Fine Chemicals
基金 广东省重点科技攻关项目(2003C104043)
关键词 1H-咪唑并[4 5-c]喹啉 2 4-二羟基喹啉 咪喹莫特 免疫调节剂 1H-imidazo [ 4,5-c ] -quinoline 2,4-dihydroxyquinoline imiquimod immune response modifier
  • 相关文献

参考文献7

二级参考文献63

  • 1朱学骏,孔繁荣,季素珍,白义杰,李正刚,吴长山.尤脱欣与疣敌治疗尖锐湿疣的疗效比较[J].中华皮肤科杂志,1994,27(3):199-200. 被引量:7
  • 2杨文彪,徐广坤.CO_2激光浅表凝固法治疗外生殖器尖锐湿疣[J].中华皮肤科杂志,1994,27(3):174-174. 被引量:16
  • 3[1]BEUTNER KR, SPRUANCE SL, HOUGHAM AJ,et al.Treatment of genital warts with an immune-response modifier(imiquimod)[J].J Am Acad Dermatol,1998,38(2Pt 1):230-239.
  • 4[2]TYRING SK.Immune response modification:imiquimod[J].Aust J Dermatol,1998,39 Suppl 1:S11-S13.
  • 5[3]BEUTNER KR, FERENCZY A.Therapeutic approaches to genital warts[J].Am J Med, 1997,102(5A):28-37.
  • 6[4]IMBERTSON LM,BEAURLINE JM, COUTURE AM,et al.Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.
  • 7[5]TYRING SK, ARANY I,STANLEY MA,et al.A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod[J].J Infect Dis,1998,178(2):551-555.
  • 8[6]ARANY I, TYRING SK, STANLEY MA,et al.Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%[J].Antiviral Res, 1999,43(1):55-63.
  • 9[7]BOTTREL RL, YANG YL, LEVY DE,et al.The immune response modifier imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6[J].Antimicrob Agents Chemother, 1999,43(4):856-861.
  • 10[8]ARANY I, TYRING SK,BRYSK MM,et al.Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier(Imiquimod) in genital warts[J].Antimicrob Agents Chemoter,2000,44(7):1869-1873.

共引文献135

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部